Literature DB >> 9390202

Active and indolent chronic lymphocytic leukaemia--immune and hormonal peculiarities.

H Everaus1, E Luik, J Lehtmaa.   

Abstract

A group of 138 B cell chronic lymphocytic leukaemia (B-CLL) patients, 83 with active disease and 53 having the indolent form of the disease, were evaluated. The aim of the study was to clarify whether indolent and active B-CLL differ in their immune and hormonal characteristics. Peripheral blood lymphocyte proliferation in response to phytohaemagglutinin, concanavalin A, recombinant interleukin-2, dextran sulphate, Pisum sativatum agglutinin and wheat germ agglutinin was investigated. Serum immunoglobulin and beta 2 microglobulin levels were determined. Adrenocorticotropic hormone (ACTH), cortisol, follicle-stimulating hormone luteinizing hormone, 17 beta-oestradiol, testosterone, triiodothyronine, thyroxine, thyroglobulin and thyrotropic hormone levels were determined by radioimmunoassay. Active and indolent CLL presented differences in immunological characteristics, as demonstrated by the more severe suppression of T lymphocyte function, reduced IgA level and considerably higher serum beta 2-microglobulin values in active disease. Immune disturbances were accompanied by hormonal imbalance, depending on disease status: lower ACTH, cortisol and triiodothyronine levels were established to occur in active CLL compared to indolent disease. Male patients demonstrated striking changes in sex hormones, which were more evident in active disease. The findings point to the complexity of immuno-hormonal disturbances in CLL with differences in the active and indolent state of the disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9390202     DOI: 10.1007/s002620050409

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  1 in total

1.  Adenosine Deaminase Activity in Chronic Lymphocytic Leukemia and Healthy Subjects.

Authors:  Bayazid Ghaderi; Sabrieh Amini; Farzad Maroofi; Chiya Jalali; Mitra Javanmardi; Daem Roshani; Mohammad Abdi
Journal:  Iran J Cancer Prev       Date:  2016-06-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.